Wave Life Sciences to Host Virtual Research Day on Wednesday, November 4, 2026
Key Highlights
- ➤Wave Life Sciences will host virtual Research Day on November 4, 2026.
- ➤Research Day will present new data across Wave’s RNA medicines platform.
- ➤Wave’s pipeline includes obesity, alpha-1 antitrypsin deficiency, and PNPLA3 liver disease programs.
- ➤Arun J. Sanyal will discuss PNPLA3 I148M liver disease and RNA editing correction.
Expert Statements
Arun J. Sanyal, Z Reno Vlahcevic Professor of Medicine and Director of the Stravitz-Sanyal Institute for Liver Disease and Metabolic Health at Virginia Commonwealth University School of Medicine
“perspectives on PNPLA3 I148M liver disease and the opportunity for an RNA editing correction approach”
CAMBRIDGE, Mass., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences, Inc. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, announced it will host a virtual Research Day on Wednesday, November 4, 2026 at 9:30 a.m. ET.
During the event, Wave will share new data highlighting its differentiated RNA medicines platform, including its best-in-class chemistry, hepatic and extra-hepatic capabilities, and RNAi, RNA editing, and bifunctional modalities. The event will also feature perspectives on PNPLA3 I148M liver disease and the opportunity for an RNA editing correction approach from Arun J. Sanyal, MD, FAASLD, a leading hepatologist. Dr. Sanyal is a Z Reno Vlahcevic Professor of Medicine and Director of the Stravitz-Sanyal Institute for Liver Disease and Metabolic Health at Virginia Commonwealth University (VCU) School of Medicine.
Get started
Create a free account to read the full story.